No Data
No Data
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Business Is Trailing The Market But Its Shares Aren't
Jefferies Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $40
Supernus Pharmaceuticals (NASDAQ:SUPN) Shareholders Have Earned a 9.4% CAGR Over the Last Five Years
Cantor Fitzgerald Initiates Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Announces Target Price $57
Express News | Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (Viloxazine) in Canada
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree (Viloxazine) in Canada
No Data